Author of

• 10692

  +

  P1.08 - Poster Session 1 - Radiotherapy (ID 195)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Radiation Oncology + Radiotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10710

    +

    P1.08-018 - Postoperative radiotherapy in T3N0 non-small-cell lung cancer: prognostic value of tumor size and costal pleural invasion (ID 2102)

    09:30 - 09:30  |  Author(s): I.J. Lee
    • Abstract

    Background
    This study was conducted to identify prognostic factors in resected NSCLC T3N0, and to determine what factors were related to postoperative radiotherapy (RT) outcome.

    Methods
    Non-small-cell lung cancer (NSCLC) T3N0 patients (n=102) who underwent resection between January 1990 to October 2009 at four hospitals were enrolled. The median tumor size was 5 cm (range 1-15). Postoperative chemotherapy (CT) and radiotherapy (RT) were given in 51.0% and 55.9% of cases, respectively. The median follow-up was 43.7 months.

    Results
    Forty two patients (41.2%) experienced recurrence. Large tumor size (> 7 cm) and costal pleural invasion were associated with a higher relapse rate (p=0.015 and p=0.077, respectively). The 5-year overall survival (OS) was 46.6%. Tumor size and pleural invasion were significant prognostic factors for overall survival (p=0.003 and p=0.044, respectively). Patients with costal pleural invasion tended to have worse survival than others (5-year OS: 42.8% vs. 48.9%, p=0.117). CT and RT did not affect OS (p=0.122 and p=0.584). The patients that had moderate to large tumors (≥ 3 cm) combined with costal pleural invasion had decreased OS after postoperative RT (p=0.046) compared with others.

    Conclusion
    In postoperative T3N0M0 patients, tumor size is an independent prognostic factor and predicts survival. The primary tumor site also tends to be related to treatment outcomes. Pleural invasion was associated with lower survival. PORT should be avoided in moderate to large size (≥3 cm) tumors with costal parietal pleura invasion.